FDA
-
-
-
-
-
-
-
Median Technologies Announces Collaboration With Tempus to Expand Access to eyonis® LCS Software as a Medical Device in the United States
-
-
-
-
-
-
-
Median Technologies adds Lion Point Capital founder to board
-
-
-
-
-
-
-
Median Technologies Files European Application for Class IIb CE Marking of Its AI-Based Software as a Medical Device for Lung Cancer Screening, eyonis® LCS
-
-
-
-
-
-
-
Median Technologies: eyonis™ Lung Cancer Screening (LCS) Meets Primary Endpoint in RELIVE Clinical Trial, the Final Pivotal Study Required for Regulatory Submissions
-
-
-
-
-
-
-
Median Technologies to Attend and Present at the ESMO Congress 2024, Being Held in Barcelona, Spain, from Sept 13-17, 2024
-
-
-
-
-
-
-
Median Technologies Reports Excellent Results from Its Independent Verification Study
-
-
-
-
-
-
-
Median Technologies to present new and breakthrough results for its iBiopsy® Lung Cancer Screening CADe/CADx Software as Medical Device at the European Congress of Radiology, taking place March 1-5 2
-
323,895 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

